Alivus Life Sciences Limited has announced the initiation of the closing under its Share Purchase Agreement to acquire a significant stake in IQGEN-X Pharma Private Limited. The company has successfully acquired 7,36,096 equity shares, representing 65.01% of IQGEN-X’s issued and paid-up equity share capital. Consequently, IQGEN-X Pharma Private Limited has officially become a subsidiary of Alivus Life Sciences Limited, effective from November 11, 2026.
Alivus Life Sciences Completes Major Acquisition
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has made a significant move in its strategic expansion by initiating the closing of its Share Purchase Agreement. This agreement was initially announced on August 18, 2026, and pertains to the acquisition of a substantial stake in IQGEN-X Pharma Private Limited.
Acquisition Details and Subsidiary Status
The company has successfully acquired 7,36,096 equity shares in IQGEN-X Pharma. This acquisition represents 65.01% of the total issued and paid-up equity share capital of IQGEN-X. The remaining share capital is slated for acquisition in due course. As a result of this transaction, IQGEN-X Pharma Private Limited is now officially recognized as a subsidiary of Alivus Life Sciences Limited, with the status effective from November 11, 2026.
This strategic acquisition is expected to strengthen Alivus Life Sciences’ position in the pharmaceutical sector and contribute to its overall growth and market presence.
Source: BSE
